慢病毒介导脯氨酰寡肽酶过表达抑制硫代乙酰胺诱导的大鼠肝纤维化*

doi:10.3969/j.issn.1672-5069.2015.02.015

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (2): 168-172.doi: 10.3969/j.issn.1672-5069.2015.02.015

慢病毒介导脯氨酰寡肽酶过表达抑制硫代乙酰胺诱导的大鼠肝纤维化^*

王晶, 周达, 丁永年, 彭媛媛, 何岭楠, 陈源文, 范建高

200092 上海市上海交通大学医学院附属新华医院消化内科（王晶,周达,何岭楠,陈源文,范建高）; 新疆医科大学第二附属医院消化内科（彭媛媛,丁永年）

收稿日期:2014-11-11 出版日期:2015-03-10 发布日期:2016-02-19
通讯作者: 陈源文,Email：shsmus@263.net
作者简介:王晶,女,26岁,硕士研究生。主要从事慢性肝损伤与肝纤维化机制研究。 Email：jingjing9236@126.com
基金资助:
国家自然科学基金项目（81170410; 81260081）; 上海市卫生系统优秀青年人才培养计划项目（XYQ2011010）; 新疆维吾尔自治区高校科研计划重点项目（XJEDU2012I001）

Lentivirus-mediated prolyl oligopeptidase overexpression attenuates thioacetamide -induced hepatic fibrosis in rats

Wang Jing, Zhou Da, Ding Yongnian, et al.

Department of Gastroenterology,Xinhua Hospital, Shanghai Jiaotong University School of Medicine,Shanghai 200092,China

Received:2014-11-11 Online:2015-03-10 Published:2016-02-19

摘要/Abstract

摘要： 目的探讨慢病毒介导的脯氨酰寡肽酶（POP）过表达对硫代乙酰胺（TAA）诱导的大鼠肝纤维化模型的影响。方法 40只雄性SD大鼠被随机分为4组,采用5%TAA诱导大鼠肝纤维化模型,各组分别在造模第1 w末门静脉注射生理盐水（正常对照组和TAA模型组）、空病毒（TAA模型+空病毒组）或携POP慢病毒（TAA模型+POP慢病毒组）,在造模第4 w末处死动物,留取肝脏组织;采用苏木素-伊红（HE）染色及Masson染色观察肝脏病理形态学变化,采用化学比色法测定肝组织内羟脯氨酸含量,分别采用实时定量PCR或Western blot法检测POP mRNA表达或蛋白水平。结果模型组POP蛋白相对表达量较正常对照组水平显著降低（P<0.05）,而POP转基因组POP蛋白水平较其余三组均显著升高（P<0.01）;POP mRNA相对表达变化与POP蛋白相一致。TAA模型组和空病毒组的纤维化评分多为Ⅱ级,肝纤维化半定量积分分别为（15.2±1.69）和（15.3±4.62）,显著高于正常对照组（1.75土0.63）和POP慢病毒过表达载体组（7.75±2.71）（P<0.05）;模型组和空病毒组肝组织羟脯氨酸含量分别为（504.47±111.15）μg/g肝质量和（498.32±90.87）μg/g肝质量,均显著高于正常对照组[（298.20±47.47） μg/g肝质量,P<0.05],而POP转基因组大鼠肝组织中羟脯氨酸含量为（383.52±43.49） μg/g肝质量,显著低于模型组和空病毒组（P<0.05）。结论肝纤维化时肝组织内POP水平下调,慢病毒载体可成功介导POP在大鼠肝组织内过表达,抑制TAA诱导的大鼠肝纤维化,降低肝组织羟脯氨酸水平。

关键词: 肝纤维化, 脯氨酰寡肽酶, 慢病毒, 过表达, 硫代乙酰胺

Abstract: Objective To investigate the effects of lentivirus-mediated prolyl oligopeptidase overexpression on thioacetamide （TAA）-induced liver fibrosis in rats. Methods 40 male Sprague-Dawley （SD） rats were randomly divided into four groups. Thioacetamide（TAA,5%） was injected intraperitoneally to induce liver fibrosis in rats. After 1-week TAA/saline treatment,rats were given normal saline（normal control group and TAA model group）,empty virus（TAA plus empty vector group）,or lentivirus containing POP gene（lentivirus-POP）（TAA plus lentivirus-POP group）;Rats were sacrificed 4 weeks after initial TAA/saline treatment; Pathological changes of the liver were examed by HE staining and Masson staining;Hydroxyproline content in liver tissues were detected by chemical colorimetric;Real-time PCR and Western blot were used to determinate POP mRNA expression and POP protein content in liver,respectively. Results Relative level of POP protein in model group was（0.123±0.04）,significantly decreased compared with normal control[（0.189±0.052）,P<0.05];POP protein level in rats received lentivirus-POP was（0.304±0.044）,significantly higher than that of other groups（P<0.01）;the changes in POP mRNA expression was similar with POP protein content. The fibrosis grade in TAA model group and empty virus group were mostly of S2,and the semi-quantitative analysis of the fibrotic tissue by Masson staining were （15.2±1.69） and （15.3±4.62）,respectively,which were significantly higher than those of the normal controls and TAA plus lentivirus-POP group[（1.75土0.63） and（7.75±2.71）,P<0.05];Hydroxyproline content in model group and empty virus group were[（504.47±111.15） μg/g wet liver weight] and[（498.32±90.87） μg/g wet liver weight],respectively, significantly higher than that of the normal controls[（298.20±47.47） μg/g wet liver weight,P<0.05],while hydroxyproline content in TAA plus lentivirus-POP group was[（383.52±43.49） μg/g TAA wet liver weight],significantly lower than those of model group and empty virus group（P<0.05）. Conclusions POP expression decreases in fibrotic liver induced by TAA;POP can be successfully overexpressed in rat liver by lentivirus containing POP genes,attenuates TAA-induced liver fibrosis and decreases hydroxyproline content in the rat liver.

Key words: Liver fibrosis, Prolyl oligopeptidase, Lentivirus, Overexpression, Thioacetamide

王晶, 周达, 丁永年, 彭媛媛, 何岭楠, 陈源文, 范建高. 慢病毒介导脯氨酰寡肽酶过表达抑制硫代乙酰胺诱导的大鼠肝纤维化^*[J]. 实用肝脏病杂志, 2015, 18(2): 168-172.

Wang Jing, Zhou Da, Ding Yongnian, et al.. Lentivirus-mediated prolyl oligopeptidase overexpression attenuates thioacetamide -induced hepatic fibrosis in rats[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 168-172.

参考文献

[1] Wells RG.Liver fibrosis:challenges of the new era.Gastroenterology,2009,136:387-388.
[2] Friedman S L. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol,2010,7（8）:425-436.
[3] Thompson A J,Patel K. Antifibrotic therapies: will we ever get there. Curr Gastroenterol Rep,2010,12（1）:23-29.
[4] Kim K H,Kim N D,Seong B L. Discovery and development of anti-HBV agents and their resistance. Molecules,2010,15（9）: 5878-5908.
[5] Mason A L,Zhang G. Linking human beta retrovirus infection with primary biliary cirrhosis. Gastroenterol Clin Biol,2010,34（6-7）:359-366.
[6] Schuppan D,Gorrell M D,Klein T,et al. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int,2010,30（6）:795-808.
[7] D'agostino G,Kim J D,Liu Z W,et al. Prolyl endopeptidase-deficient mice have reduced synaptic spine density in the CA1 region of the hippocampus,impaired LTP,and spatial learning and memory. Cereb Cortex,2013,23（8）:2007-2014.
[8] Goossens F,De Meester I,Vanhoof G,et al. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem,1996,34（1）:17-22.
[9] Chen Y W,Liu B W,Zhang Y J,et al. Preservation of basal AcSDKP attenuates carbon tetrachloride-induced fibrosis in the rat liver. J Hepatol,2010,53（3）:528-536.
[10] Suzuki Y,Katagiri F,Sato F,et al. Significant decrease in plasma N-acetyl-seryl-aspartyl-lysyl-proline level in patients with end stage renal disease after kidney transplantation. Biol Pharm Bull,2014,37（6）:1075-1079.
[11] 中华医学会传染病与寄生虫病学分会、肝病学分会联合修订. 病毒性肝炎防治方案. 中华内科杂志,2001,40（1）:62-688.
[12] 中华肝脏病学会肝纤维化学组.肝纤维化诊断及疗效评估共识.中华肝脏病杂志,2002,10:327-328.
[13] Friedman S L. Liver fibrosis-from bench to bedside. J Hepatol,2003,38 Suppl 1:S38-53.
[14] Thompson AJ,Patel K. Antifibrotic therapies:will we ever get there Curr Gastroenterol Rep,2010,12（1）:23-29.
[15] Schuppan D,Gorrell MD,Klein T,et al. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int,2010,30（6）:795-808.
[16] Miranda-Mendez A,Lugo-Baruqui A,Armendariz-Borunda J. Molecular basis and current treatment for alcoholic liver disease. Int J Environ Res Public Health,2010,7（5）:1872-1888.
[17] Matsubara S,Takahashi T,Kimura A P. Localization and subcellular distribution of prolyl oligopeptidase in the mouse placenta. J Mol Histol,2011,42（3）:251-264.
[18] Matsuda T,Sakaguchi M,Tanaka S,et al. Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death. Int J Biochem Cell Biol,2013,45（4）:850-857.
[19] Wynn T A,Barron L. Macrophages:master regulators of inflammation and fibrosis. Semin Liver Dis,2010,30（3）:245-257.
[20] Yamakawa N,Shimeno H,Soeda S,et al. Regulation of prolyl oligopeptidase activity in regenerating rat liver. Biochim Biophys Acta,1994,1199（3）:279-284.
[21] Matsubara Y,Ono T,Tsubuki S,et al. Transient up-regulation of a prolyl endopeptidase activity in the microsomal fraction of rat liver during postnatal development. Eur J Biochem,1998,252（1）:178-183.
[22] Agirregoitia N,Casis L,Gil J,et al. Ontogeny of prolyl endopeptidase and pyroglutamyl peptidase I in rat tissues. Regul Pept,2007,139（1-3）:52-58.
[23] Myohanen T T,Venalainen J I,Garcia-Horsman J A, et al. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol,2008,130（5）:993-1003.
[24] Yang L,Magness ST,Bataller R,et al. NF-kappaB activation in Kupffer cells after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol,2005,289（3）:G530-538.
[25] Myohanen TT,Venalainen JI,Garcia-Horsman JA,et al. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol,2008,130（5）:993-1003.
[26] Rath NC,Kannan L,Liyanage R,et al. Thymosin beta in macrophage. J Endocrinol Reprod,2007,11（2）:55-61.
[27] Barrett AJ,Rawlings ND. Oligopeptidases,and the emergence of the prolyl oligopeptidase family. Biol Chem Hoppe Seyler,1992,373（7）:353-360.

慢病毒介导脯氨酰寡肽酶过表达抑制硫代乙酰胺诱导的大鼠肝纤维化^*

Lentivirus-mediated prolyl oligopeptidase overexpression attenuates thioacetamide -induced hepatic fibrosis in rats

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[3]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[4]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[5]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[6]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[7]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[8]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[9]	周丽云, 李校天, 李丽, 杨俊超. 1,25（OH）₂D₃通过调节miR-146a水平抑制大鼠肝纤维化的体内和体外观察[J]. 实用肝脏病杂志, 2019, 22(3): 333-336.
[10]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[11]	玉苏甫·吐尔逊, 赵燕霞. 小剂量二乙基亚硝胺诱导大鼠肝纤维化模型的建立[J]. 实用肝脏病杂志, 2019, 22(1): 33-36.
[12]	郭晓霞, 郭琲婷, 孔祥璐. 脾切除对原发性胆汁性肝硬化小鼠肝组织纤维化影响研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 837-841.
[13]	刘恩强, 陈果, 廖修用, 许美凤, 魏贵玉, 罗小平. 虾青素对肝纤维化大鼠的保护作用及机制研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 842-846.
[14]	黄春明, 杨湛, 聂玉强, 胡中伟, 周永健, 詹远京, 郭家伟, 余卫华. γ-谷氨酰转肽酶/血小板比值对血清转氨酶正常的慢性HBV感染者肝纤维化的预测价值分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 859-862.
[15]	潘高峰综述, 傅茂英, 郜玉峰审校. 内质网应激与肝纤维化关系研究进展^*[J]. 实用肝脏病杂志, 2018, 21(6): 987-990.